MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In


News Categories




FDA Sets Review Date for New COPD Drug, Anoro Ellipta

Approval decision expected in December (Feb. 19)

The FDA has accepted the new drug application (NDA) for an investigational once-daily LAMA/LABA combination medicine — umeclidinium bromide and vilanterol (UMEC/VI, GlaxoSmithKline/Theravance) — for patients with chronic obstructive pulmonary disease (COPD).

The Prescription Drug User Fee Act (PDUFA) goal date is December 18, 2013.

UMEC/VI — with the proposed brand name of Anoro — is a combination of two investigational bronchodilator molecules: umeclidinium bromide (formerly known as GSK573719, a long-acting muscarinic antagonist [LAMA]) and vilanterol (a long-acting beta2 agonist [LABA]). The combo drug is administered using the Ellipta inhaler.

Source: GSK; February 19, 2013.

More stories